Qube Research & Technologies (QRT)
EGRX

Qube Research & Technologies (QRT)’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16,763
Closed -$93.9K – 4320
2024
Q2 		$93.9K Buy
16,763
+13,212
+372% +$57.5K ﹤0.01% 2617
2024
Q1 		$18.6K Sell
3,551
-12,296
-78% -$67.5K ﹤0.01% 3710
2023
Q4 		$82.9K Sell
15,847
-1,937
-11% -$19.1K ﹤0.01% 3158
2023
Q3 		$280K Sell
17,784
-14,592
-45% -$262K ﹤0.01% 2278
2023
Q2 		$629K Buy
32,376
+3,667
+13% +$87K ﹤0.01% 1458
2023
Q1 		$814K Sell
28,709
-3,722
-11% -$110K ﹤0.01% 1373
2022
Q4 		$948K Sell
32,431
-5,899
-15% -$188K 0.01% 1246
2022
Q3 		$1.01M Buy
+38,330
New +$1.41M 0.01% 1194
2022
Q2 		– Sell
-7,158
Closed -$354K – 3253
2022
Q1 		$354K Sell
7,158
-2,635
-27% -$126K ﹤0.01% 1701
2021
Q4 		$499K Buy
+9,793
New +$507K ﹤0.01% 1570
2021
Q2 		– Sell
-6,729
Closed -$281K – 2900
2021
Q1 		$281K Buy
6,729
+1,209
+22% +$56.1K ﹤0.01% 1493
2020
Q4 		$257K Buy
+5,520
New +$258K ﹤0.01% 1418

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Qube Research & Technologies (QRT)'s EGRX Position: Q3 2024 in Review

Qube Research & Technologies (QRT) sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2024, closing a stake of 16,763 shares — an estimated $93.9K sold.

Qube Research & Technologies (QRT) first reported a position in EGRX in Q4 2020 and held it in 12 quarters. The position peaked at $1.01M in Q3 2022. 65 funds tracked by Wall St. Rank hold EGRX as of Q3 2024.

  • Qube Research & Technologies (QRT) reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 16,763 Eagle Pharmaceuticals, Inc. shares in Q3 2024, an estimated $93.9K.
  • Qube Research & Technologies (QRT) first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2020 and held it in 12 quarters.
  • Qube Research & Technologies (QRT)'s Eagle Pharmaceuticals, Inc. position peaked at $1.01M in Q3 2022.
  • 65 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2024, filed 14 Nov 2024.